Epilepsy Talk

Increased Birth Defect Risks in Two FDA-Approved Epilepsy Medications | October 20, 2011

Two epilepsy drugs – Lamictal and Keppra – which are currently listed in category C may be dangerous to a fetus and should be listed in category D, according to new data. The difference between the categories is that D shows evidence of risk, but the benefits outweigh the risks. While category C is indicated for drugs that have shown to be harmful in animal studies…

http://central-pennsylvania.injuryboard.com/fda-and-prescription-drugs/increased-birth-defect-risks-in-two-fdaapproved-epilepsy-medications.aspx?googleid=295210


2 Comments »

  1. How did or do they determine that “possible” temporary benefits, out weigh permenant risks?

    Like

    Comment by mkfarnam — October 21, 2011 @ 1:24 AM

  2. Linguistics!

    Like

    Comment by Phylis Feiner Johnson — October 21, 2011 @ 1:44 PM


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

    About the author

    Phylis Feiner Johnson

    Phylis Feiner Johnson

    I've been a professional copywriter for over 35 years. I also had epilepsy for decades. My mission is advocacy; to increase education, awareness and funding for epilepsy research. Together, we can make a huge difference. If not changing the world, at least helping each other, with wisdom, compassion and sharing.

    View Full Profile →

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,447 other followers

    Follow Epilepsy Talk on WordPress.com
%d bloggers like this: